Study Stopped
Astora business is closing
Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse
Harmony 522
A Prospective, Safety and Efficacy Cohort Study of Elevate® Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair
1 other identifier
interventional
99
1 country
23
Brief Summary
The aim of this study is to further evaluate the safety and efficacy of the Elevate® Apical and Posterior Prolapse Repair System for repair of apical/posterior pelvic organ prolapse in a controlled, post-market cohort study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Apr 2014
Longer than P75 for phase_4
23 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 24, 2014
CompletedFirst Posted
Study publicly available on registry
April 28, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2019
CompletedSeptember 7, 2016
September 1, 2016
5 years
April 24, 2014
September 6, 2016
Conditions
Outcome Measures
Primary Outcomes (2)
Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures
36 months
Rate of device or procedure related serious adverse events
36 months
Secondary Outcomes (3)
Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures
36 months
Rate of repeat surgery/revision for prolapse arising from the same site/target compartment
36 months
Changes in Quality of Life measured through the following questionaires: PFDI- 20,PFIQ-7, PISQ-12
36 months
Other Outcomes (3)
Subjects experiencing adverse events related to device or procedure
36 months
Subjects experiencing vaginal bulge
36 months
Subjects experiencing prolapse at or beyond the hymenal ring [Time Frame: 36 months
36 months
Study Arms (2)
Elevate Apical and Posterior
ACTIVE COMPARATORThe experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
Native Tissue Repair
ACTIVE COMPARATORThe control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
Interventions
Eligibility Criteria
You may qualify if:
- Subject is female
- Subject is at least 18 years of age
- Subject must have documented diagnosis of posterior or posterior and apical vaginal prolapse with leading edge of pelvic organ prolapse at or beyond the hymen. At or beyond the hymen is defined as POP-Q scores of Bp ≥ 0; or Bp ≥ 0 and C ≥ -1/2 TVL (for a multi-compartment posterior prolapse that includes the apical compartment)
- Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit")
- Subject or subject's legally authorized representative is willing to provide written informed consent
- Subject is willing and able to comply with the follow-up regimen
You may not qualify if:
- Subject is pregnant or intends to become pregnant during the study
- Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis
- Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)
- Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area
- Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)
- Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan's syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)
- Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis
- Subject has uncontrolled diabetes mellitus (DM)
- Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)
- Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse (colpocleisis)
- Subject is not able to conform to the modified dorsal lithotomy position
- Subject is currently participating in or plans to participate in another device or drug study during this study
- Subject has a known sensitivity to polypropylene
- Subject has had previous prolapse repair with mesh in the target compartment
- Subject is planning to undergo a concomitant repair with use of mesh in the non-target compartment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (23)
Urological Associates of Southern Arizona
Tucson, Arizona, 85941, United States
The Clark Center for Urogynecology
Newport Beach, California, 92663, United States
Yale School of Medicine
New Haven, Connecticut, 06520, United States
National Center for Advanced Pelvic Surgery
Washington D.C., District of Columbia, 20010, United States
Women's Health Advantage
Fort Wayne, Indiana, 46825, United States
Metro Urology
Woodbury, Minnesota, 55125, United States
Adult & Pediatric Urology and Urogynecology
Omaha, Nebraska, 68114, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, 89169, United States
Delaware Valley Urology
Mount Laurel, New Jersey, 08054, United States
Princeton Medical Center
Princeton, New Jersey, 08540, United States
The Center for Specialized Women's Health
Whippany, New Jersey, 07981, United States
North Shore Women's Health Clinic
Great Neck, New York, 11021, United States
Premier Medical Group
Poughkeepsie, New York, 12601, United States
The Institute for Female Pelvic Medicine - St. Luke's Hospital
Allentown, Pennsylvania, 18103, United States
Center for Women's Health of Lansdale
Lansdale, Pennsylvania, 19446, United States
The Female Pelvic Health Center
Newtown, Pennsylvania, 18940, United States
Swan Urogynecology
Nashville, Tennessee, 37203, United States
The Womens Centre
Denton, Texas, 76210, United States
University of Texas at Galveston
Galveston, Texas, 77555, United States
Lone Star Urogynecology and Continence Center
Round Rock, Texas, 78665, United States
Female Pelvic Medicine Institute of Virginia
North Chesterfield, Virginia, 23235, United States
Athena Women's Health
Issaquah, Washington, 98027, United States
University of Washington Pelvic Health Center
Seattle, Washington, 98195, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eric R Sokol, MD
Stanford University
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 24, 2014
First Posted
April 28, 2014
Study Start
April 1, 2014
Primary Completion
April 1, 2019
Study Completion
April 1, 2019
Last Updated
September 7, 2016
Record last verified: 2016-09
Data Sharing
- IPD Sharing
- Will share
Data will be shared at a later data by the American Urogynecology Society aggregated with other data extracted from a national registry database.